The advancement of dual and multi-receptor agonists, such as tirzepatide, signifies the most recent progression in this therapeutic category, demonstrating enhanced effectiveness in metabolic regulation and weight control
Medicare historically has not covered anti-obesity medications, though legislative efforts are underway to change this
No NAFLD patient had clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, or a serum bilirubin level greater than twice the upper limit of normal
Is orforglipron a peptide
Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, Ogawa H et al (2010) 5-fu metabolism in cancer and orally-administrable 5-FU drugs